Showing posts with label HPV. Show all posts
Showing posts with label HPV. Show all posts

Tuesday, April 28, 2015

Another Study Heralds Early Benefits of HPV Vaccine in Preventing Cervical Dysplasia and Anogenital Warts

By: Lewis First, MD, MS; Editor-in-Chief    

          Our journal, like others, has published a number of studies demonstrating the benefits of human papillomavirus (HPV) vaccine but there is minimal information published about the effectiveness of the vaccine using a large population-based cohort, that is until this week when we share the results of a large study by Smith et al. (doi: 10.1542/peds.2014-2961) of eighth grade girls in Ontario, Canada before and after an eighth grade vaccination program was instituted.   
     The authors chose to look at absolute risk differences, relative risks, and the 95% confidence intervals attributable to vaccination in girls eligible for this program and then examined these girls again in grades 10-12 for cervical dysplasia and anogenital warts comparing them to those who were unvaccinated.  The results are impressive and demonstrate strong evidence of the benefits of early vaccination against HPV. 
       If you need nice proof that the HPV vaccine can make a difference—check this study out and then share it with your teen patients and their parents who might be hesitant to consent to getting this important vaccine.

Related Links:

Friday, August 22, 2014

Two Studies on HPV Vaccines Inject Some New Information Worth Sharing with Patients

By: Lewis First, MD, MS; Editor-in-Chief 

Photo by James Gathany for the US CDC
Recently, Assistant Surgeon General Anne Schuchat, MD, who is also Director of the National Center for Immunization and Respiratory Diseases for the Centers for Disease Control and Prevention spoke at our children’s hospital, the Vermont Children’s Hospital, on the successes and challenges of our national immunization program.

Up front as a national challenge was the inability to get more teens vaccinated against human papilloma virus (HPV) despite the important role this vaccine plays in reducing cervical and genital cancers. To help overcome this challenge, we are publishing two studies this week on the HPV vaccine.

The first is a long-term safety, immunogenicity, and effectiveness study of a quadrivalent HPV vaccine by Ferris et al. (doi: 10.1542/peds.2013-4144). Teens and pre-teens ages 9-15 received a series of HPV4 vaccines or placebo (with the placebo group getting the vaccine after 30 months into the study) with both cohorts followed for eight years to determine the persistence of high serologic levels of the strains of HPV in the vaccine as well as the effectiveness in preventing HPV infection.

The good news is persistence of protection for at least eight years with no adverse events—suggesting the safety and immunogenicity of this vaccine as well as its ongoing effectiveness is well-worth sharing with parents who worry about the risks more than the benefits of having their teens get this vaccine.

The second study by Perkins et al. (doi: 10.1542/peds.2014-0442) chose to focus on those families who do worry about giving this vaccine to their adolescents or at least delay the administration of the vaccine for later than the recommended age (prior to onset of sexual activity). The authors performed qualitative interviews and found that some of the leading reasons why families had the vaccine delayed was not because they did not believe in its importance, but because their physician did not recommend it or agreed to wait until a teen became sexually active before giving it.

Hopefully, if you are reading this blog, you are not in the group of providers hampering the appropriate administration of this vaccine (at ages 11 to 12), but if you have been delaying its administration or forgetting to mention it, take a shot at reading this study and reducing your HPV missed opportunities to vaccinate at the appropriate 11 or 12 year visit.

Related Reading: